# TRIANA Biomedicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triana-biomedicines

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.trianabio.com
- Total disclosed funding: $43M
- Latest round: Series A (Apr 19, 2022)
- Investors on record: 6

## About

Founded in 2019 and based in Massachusetts, US, TRIANA Biomedicines, Inc. is a biopharmaceutical company that develops a molecular glue discovery platform to help regulate disease. In April 2022, TRIANA Biomedicines, Inc. raised an undisclosed amount of Seed funding from RA Capital Management and Atlas Venture and this round was part of a larger USD 110 million Seed and Series A funding. As of 2022, Patrick Trojer is the president and CEO of the company.

The company offers a technology that enables the identification of molecules that promote the interaction of a target and another protein in such a way that the fate or function of the target protein is altered. The firm's rational approach to molecular glue discovery is centered on inducing or enhancing the degradation of high-profile cancer targets.

The organization plans to use the April 2022 funding to support its molecular glue clinical candidates.

## Funding rounds

- Series A, Apr 19, 2022, $7.8M — Atlas Venture, RA Capital Management
- Series A, Jan 28, 2022, $35M — Atlas Venture, Lightspeed Venture Partners, Pfizer Venture Investments, RA Capital Management, Surveyor Capital, Logos Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Surveyor Capital — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A